Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYC | P01106 | 1/20 | 0.31 |
| ▸ | WDR5 | P61964 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6840009 | 0.80 | MEN1 (0.41) | ALDH1A1 | |
| SCHEMBL6842528 | 0.79 | — | — | |
| SCHEMBL6840024 | 0.76 | KDM4E (0.46) | MYCWDR5KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL6835784 | 0.74 | KDM4E (0.32) | MYCWDR5KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5777962 | 0.73 | ALDH1A1 (0.52) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL15653814 | 0.73 | CDK4 (0.50) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL5819549 | 0.72 | TGFBR1 (0.55) | MYCWDR5KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL30309300 | 0.71 | TGFBR1 (0.51) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL1850971 | 0.71 | TGFBR1 (0.51) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL18230478 | 0.70 | CCR1 (0.49) | MYCWDR5KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040181066-A1 | Tyrosine kinase inhibitors | FRALEY MARK E (US) | 2004-09-16 | — | — | US | disclosed |
| WO-2003011838-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040181066-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | MYC 684/4885WDR5 2602/4885KDM4E 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.